BioSpace News Archive

Bio NC

Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial

Merakris Therapeutics announces it has fully enrolled the first part of a two-part clinical trial to evaluate the safety, effectiveness, and administration frequency of its investigational wound care product, Dermacyte® Amniotic Wound Care Liquid.

December 5, 2023
·
4 min read
Genetown

FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE ® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer.

December 5, 2023
·
6 min read
Drug Development

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD1,2.

December 5, 2023
·
5 min read
Biotech Beach

PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium

Prelude Corporation announced it will present data demonstrating the decision impact on physician recommendations for radiation therapy in ductal carcinoma in situ patients in Australia.

December 5, 2023
·
3 min read
Drug Development

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

Bolt Biotherapeutics, Inc. today announced that the first patient has been dosed in the Phase 2 clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC), as a single agent and in combination with the HER2-targeting antibody pertuzumab.

December 5, 2023
·
8 min read
Business

Star Therapeutics Appoints Matthew Fust as Independent Director and Board Audit Chair

Star Therapeutics today announced the appointment of Matthew Fust, a veteran finance executive in the life sciences industry, to its Board of Directors.

December 5, 2023
·
2 min read
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza

Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing.

December 5, 2023
·
4 min read
DiviTum(R) TKa in Three Posters at the World’s Largest Breast Cancer Symposium

Biovica International Biovica, active in cancer monitoring, announces that three abstracts based on studies using the blood test DiviTum® TKa will be presented at the world’s largest breast cancer symposium, SABCS, in early December.

December 5, 2023
·
3 min read
Business

Quipt Home Medical Corp. to Announce Fourth Quarter and Full Year 2023 Financial Results on December 18, 2023

Quipt Home Medical Corp. will announce its fourth quarter and full year 2023 financial results on Monday, December 18, 2023.

December 5, 2023
·
1 min read
Drug Development

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

Trevi Therapeutics, Inc. today announced the initiation of its Phase 2b CORAL clinical trial evaluating three doses of Haduvio against placebo in approximately 160 IPF patients with chronic cough.

December 5, 2023
·
6 min read